Prophylactic methylxanthines for endotracheal extubation in preterm infants

Area of Science:

• Neonatal medicine
• Respiratory support
• Pharmacology

Background:

• Weaning preterm infants from intermittent positive pressure ventilation (IPPV) is challenging due to poor respiratory drive.
• Preterm infants often experience hypercarbia and apnea, complicating extubation.
• Methylxanthine therapy may stimulate respiratory drive, aiding successful extubation.

Purpose of the Study:

• To evaluate the efficacy of prophylactic methylxanthine treatment in preterm infants undergoing extubation from IPPV.
• To assess the impact of methylxanthines on re-intubation rates and other adverse effects.
• To determine the effect on neurodevelopmental outcomes and duration of respiratory support.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) identified through comprehensive database searches.
• Inclusion criteria: Preterm or low birth weight infants undergoing extubation, comparing methylxanthines (theophylline, caffeine) with placebo or no treatment.
• Standard Cochrane Neonatal Review Group methods for data collection and analysis were employed.

Main Results:

• Methylxanthine treatment reduced extubation failure within one week (RR 0.48, NNT 4).
• Significant heterogeneity observed in meta-analysis, potentially due to varying baseline extubation failure rates.
• Caffeine administration was associated with lower rates of bronchopulmonary dysplasia, PDA ligation, cerebral palsy, and death/disability, and reduced time on respiratory support.

Conclusions:

• Methylxanthines enhance successful extubation in preterm infants within seven days.
• Methylxanthine therapy improves important neurodevelopmental outcomes.
• Future research should stratify by gestational age and evaluate caffeine against placebo.